Cost-effectiveness of ceftolozane/tazobactam compared to meropenem in ventilator-associated pneumonia
Abstract Introduction Ventilator-associated pneumonia (VAP) is a prominent cause of morbidity and mortality in intensive care unit patients. Ceftolozane/tazobactam could be a cost-effective treatment option prior to culture test result for treatment of VAP. This study aims to evaluate the cost-effec...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2025-10-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s12962-025-00658-0 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|